Detail akcie Cognition Therap Rg online

Business Summary: Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cognition Therapeutics Inc revenues was not reported. Net loss decreased 23% to $20.1M. Lower net loss reflects Developing and commercializing therapeutics segment loss decrease of 21% to $34.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.69 to -$0.31.